Assessment and prioritization of the WHO "best buys" and other recommended interventions for the prevention and control of non-communicable diseases in Iran.
Iran
Multi-criteria decision analysis (MCDA)
National action plan
Non-communicable diseases (NCDs)
Preventive interventions
Prioritization
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
14 Mar 2020
14 Mar 2020
Historique:
received:
26
08
2019
accepted:
02
03
2020
entrez:
16
3
2020
pubmed:
17
3
2020
medline:
18
6
2020
Statut:
epublish
Résumé
The WHO's "best buys" and other recommended interventions are a menu of policy options and cost-effective interventions for the prevention and control of major noncommunicable diseases (NCDs). The menu has six objectives, implementing which by member states is expected to promote the achievement of the nine NCD targets by 2025. In line with their context, countries can select from the menu of best buys and other recommended interventions. Iran adopted its national action plan on NCDs, 2015, including global as well as some specific goals and targets. This study had two objectives: analyzing the gaps to reach the national targets on NCDs; and prioritizing the best buys and other recommended interventions based on multi-criteria decision-making (MCDA) method for the context of Iran. This is a mixed-methods study. We used qualitative textual evidence (documentary content analysis) and MCDA for prioritization of interventions based on five criteria, including a number of people to be potentially affected by the intervention, cost-effectiveness of the intervention, attributable burden (DALY per 100,000), hospitalization and variations among income levels. Data related to five criteria for each intervention were extracted from national studies and relevant international organizations. The weight of each criterion determines based on the opinions of national experts. Out of 105 actions and interventions recommended by WHO, only 12 of them were not on the national agenda in Iran, while the six missed interventions were related to objective number 4. Only one of the best buys Group's interventions was not targeted (vaccination against human papillomavirus, two doses of 9-13-year-old girls), for which arrangements are being made for the implementation. Encouraging and educating healthy dietary habits and increasing public awareness about the side effects of smoking and exposure to second-hand smoke, e.g., through mass media campaigns, are among the interventions in need of serious prioritization. The priority of interventions was independently calculated in the area of risk factors and clinical preventive interventions. Due to limited resources, low and middle-income countries (LMICs) need to identify and prioritize more cost-effective and more equitable interventions to combat the NCD epidemic. Based on our findings, we advocate more investment in the mass and social media campaigns to promote a healthy diet, avoid tobacco use, as well as the inclusion of some effective clinical preventive interventions into the national action plan, along the long pathway to tackle NCDs and ultimately reach sustainable health development in Iran. The use of the MCDA approach assisted us in formulating a simultaneous use of efficiency and equity, and other indices for prioritizing the interventions.
Sections du résumé
BACKGROUND
BACKGROUND
The WHO's "best buys" and other recommended interventions are a menu of policy options and cost-effective interventions for the prevention and control of major noncommunicable diseases (NCDs). The menu has six objectives, implementing which by member states is expected to promote the achievement of the nine NCD targets by 2025. In line with their context, countries can select from the menu of best buys and other recommended interventions. Iran adopted its national action plan on NCDs, 2015, including global as well as some specific goals and targets. This study had two objectives: analyzing the gaps to reach the national targets on NCDs; and prioritizing the best buys and other recommended interventions based on multi-criteria decision-making (MCDA) method for the context of Iran.
METHODS
METHODS
This is a mixed-methods study. We used qualitative textual evidence (documentary content analysis) and MCDA for prioritization of interventions based on five criteria, including a number of people to be potentially affected by the intervention, cost-effectiveness of the intervention, attributable burden (DALY per 100,000), hospitalization and variations among income levels. Data related to five criteria for each intervention were extracted from national studies and relevant international organizations. The weight of each criterion determines based on the opinions of national experts.
RESULTS
RESULTS
Out of 105 actions and interventions recommended by WHO, only 12 of them were not on the national agenda in Iran, while the six missed interventions were related to objective number 4. Only one of the best buys Group's interventions was not targeted (vaccination against human papillomavirus, two doses of 9-13-year-old girls), for which arrangements are being made for the implementation. Encouraging and educating healthy dietary habits and increasing public awareness about the side effects of smoking and exposure to second-hand smoke, e.g., through mass media campaigns, are among the interventions in need of serious prioritization. The priority of interventions was independently calculated in the area of risk factors and clinical preventive interventions.
CONCLUSION
CONCLUSIONS
Due to limited resources, low and middle-income countries (LMICs) need to identify and prioritize more cost-effective and more equitable interventions to combat the NCD epidemic. Based on our findings, we advocate more investment in the mass and social media campaigns to promote a healthy diet, avoid tobacco use, as well as the inclusion of some effective clinical preventive interventions into the national action plan, along the long pathway to tackle NCDs and ultimately reach sustainable health development in Iran. The use of the MCDA approach assisted us in formulating a simultaneous use of efficiency and equity, and other indices for prioritizing the interventions.
Identifiants
pubmed: 32171267
doi: 10.1186/s12889-020-8446-x
pii: 10.1186/s12889-020-8446-x
pmc: PMC7071663
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333Références
J Hypertens. 2018 Dec;36(12):2380-2389
pubmed: 30005027
East Mediterr Health J. 2019 Feb 18;24(12):1172-1180
pubmed: 30799557
Health Policy. 2010 Aug;96(3):262-4
pubmed: 20206403
Data Brief. 2018 Jul 03;20:767-774
pubmed: 30211272
Value Health. 2017 Feb;20(2):266-272
pubmed: 28237207
BMC Med Inform Decis Mak. 2017 Oct 26;17(1):149
pubmed: 29073892
Lancet. 2018 Sep 22;392(10152):1072-1088
pubmed: 30264707
J Neurol. 2005 Sep;252(9):1026-32
pubmed: 15761676
Arch Iran Med. 2014 Jan;17(1):7-15
pubmed: 24444059
J Diabetes Metab Disord. 2017 Jan 23;16:3
pubmed: 28127543
Public Health. 2014 Oct;128(10):896-903
pubmed: 25369354
PLoS One. 2019 Feb 14;14(2):e0211622
pubmed: 30763320
Patient. 2010;3(4):229-248
pubmed: 21394218
Value Health. 2014 Jul;17(5):619-28
pubmed: 25128056
Value Health. 2012 Sep-Oct;15(6):961-70
pubmed: 22999148
PLoS One. 2015 Apr 21;10(4):e0124806
pubmed: 25897861
Obes Rev. 2007 May;8 Suppl 2:47-52
pubmed: 17371307
BMJ Glob Health. 2018 Feb 19;3(1):e000535
pubmed: 29527342
J Pak Med Assoc. 2018 Sep;68(9):1383-1386
pubmed: 30317270
Lancet. 2019 May 11;393(10184):1958-1972
pubmed: 30954305
BMC Health Serv Res. 2011 Nov 30;11:329
pubmed: 22129247
Pharmacoeconomics. 2016 May;34(5):435-46
pubmed: 26739955
J Health Organ Manag. 2012;26(3):363-73
pubmed: 22852458
Health Expect. 2000 Mar;3(1):37-45
pubmed: 11281910
Soc Sci Med. 2017 Sep;188:137-156
pubmed: 28772164
Iran J Pharm Res. 2016 Winter;15(1):369-81
pubmed: 27610178
Iran J Public Health. 2018 Sep;47(9):1397-1405
pubmed: 30320015
Patient. 2012;5(1):45-56
pubmed: 22185216
Health Res Policy Syst. 2012 Feb 17;10:6
pubmed: 22339981
Am J Cardiovasc Drugs. 2006;6(4):251-8
pubmed: 16913826
Curr Med Res Opin. 2009 Dec;25(12):2835-43
pubmed: 19916728
Int J Health Policy Manag. 2019 Mar 06;8(5):319-320
pubmed: 31204450
Addiction. 2016 Oct;111(10):1703-13
pubmed: 26508526
Value Health. 2012 Dec;15(8):1172-81
pubmed: 23244821
J Mark Access Health Policy. 2017 Oct 12;5(1):1360545
pubmed: 29081919
Patient. 2012;5(4):225-37
pubmed: 23098363
Lancet. 2011 Apr 23;377(9775):1438-47
pubmed: 21474174
Health Policy Plan. 2019 Jun 1;34(5):370-383
pubmed: 31199439
Patient. 2018 Aug;11(4):425-437
pubmed: 29450833
Daru. 2016 Apr 11;24:10
pubmed: 27068692